Avelumab and Merkel Cell Carcinoma: Examining Causation and Risk

From General Health to Occupational Exposure

The legacy of general health and science information has long emphasized broad public awareness and preventive education, focusing on lifestyle factors and environmental influences at a population level. Within this framework, occupational exposures were often considered secondary, addressed only when acute or visibly harmful effects emerged. However, as industrial processes have expanded and chemical agents become more prevalent in manufacturing environments, the need to refine this perspective has grown. The transition from general health context to a specific occupational exposure concern requires a shift in focus: from population-wide risk communication to targeted scrutiny of substances encountered in workplace settings. One such substance is Avelumab, a monoclonal antibody used in therapeutic contexts, which has raised questions about potential risks for workers involved in its production or handling. Studies examining Avelumab exposure and Merkel Cell Carcinoma risk represent a critical intersection of occupational health and pharmaceutical manufacturing. This pivot acknowledges that while general health information provides a foundation, the nuances of industrial exposure demand specialized investigation, moving beyond broad advisories to assess real-world implications for those in mass production environments.

Avelumab: Mechanism and Therapeutic Role

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) and functions as an immune checkpoint inhibitor (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). Approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for use in this indication, and is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Merkel Cell Carcinoma: Etiology and Treatment Landscape

Merkel cell carcinoma is a rare, highly aggressive skin cancer with neuroendocrine differentiation (https://pubmed.ncbi.nlm.nih.gov/36450381/). It is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus; approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/). The incidence rate of MCC is increasing, and MCC is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors (ICIs) offer durable responses and significant clinical benefit, with two agents—avelumab (anti-PD-L1) and pembrolizumab (anti-PD-1)—currently approved by the U.S. Food and Drug Administration for the treatment of advanced MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/). The standard treatment of metastatic MCC is the use of anti-PD-1/-PD-L1 immune checkpoint inhibitors such as pembrolizumab or avelumab, which in comparison with conventional chemotherapy show better overall response rates and longer duration of responses in patients (https://pubmed.ncbi.nlm.nih.gov/34445385/). Nevertheless, approximately 50% of patients with advanced MCC treated with ICI progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Additionally, 50% of patients do not respond or develop ICI-induced, immune-related adverse events (irAEs), due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/).

Causation and Risk: What the Evidence Shows

Mechanistic pathways linking avelumab to Merkel cell carcinoma risk are primarily related to its role as an immune checkpoint inhibitor. Avelumab blocks PD-L1, thereby enhancing T-cell responses against tumor cells. However, in the context of MCC, the drug is used as a treatment, not a cause. The evidence does not indicate that avelumab causes MCC; rather, it is a therapeutic agent for existing MCC. The risk narrative centers on the adequacy of warnings regarding avelumab and MCC, which are well-documented in prescribing information and clinical trial data. The JAVELIN Merkel 200 trial provided efficacy and safety data, and subsequent studies have evaluated outcomes in avelumab-refractory patients. For example, a multicenter study of the prospective skin cancer registry ADOREG examined ipilimumab plus nivolumab in avelumab-refractory MCC, noting that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Another retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC reported that despite advances in systemic therapy options for MCC, approximately 50% of patients with advanced MCC treated with ICI progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). In a separate report, three out of five patients with metastatic MCC refractory to avelumab responded to combined ipilimumab plus nivolumab according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/).

Implications for Affected Patients

Causation-related considerations for affected patients involve understanding that avelumab is not a causative agent for MCC but a treatment. The timeline between exposure and documented harm is relevant to adverse events rather than MCC causation. Immune-related adverse events can occur during or after treatment, but the evidence does not establish a causal link between avelumab and the development of MCC. Instead, the drug is used to treat existing MCC. The adequacy of warnings is supported by regulatory approvals and clinical trial data that outline risks, including immune-related adverse events and lack of response in some patients. For patients who progress on avelumab, alternative treatments such as combined ipilimumab plus nivolumab have been studied (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). In summary, the evidence indicates that avelumab is an approved treatment for metastatic MCC, with demonstrated efficacy in a subset of patients. The risk of MCC is not caused by avelumab; rather, the drug is used to manage the disease. Warnings regarding avelumab focus on its therapeutic use and potential adverse effects, not on MCC causation. The timeline for harm relates to immune-related adverse events during treatment, not to the development of MCC. For patients with avelumab-refractory disease, alternative immune checkpoint inhibitor combinations may offer benefit.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, avelumab is a treatment for Merkel cell carcinoma, not a cause. It is an immune checkpoint inhibitor approved for metastatic MCC. The evidence shows it is used to manage the disease, and there is no causal link between avelumab exposure and the development of MCC.

What are the risks associated with avelumab treatment?

Avelumab can cause immune-related adverse events (irAEs) due to its mechanism of blocking PD-L1. Approximately 50% of patients may not respond or develop irAEs. These risks are well-documented in prescribing information and clinical trial data (https://pubmed.ncbi.nlm.nih.gov/34445385/).

What treatment options exist for patients who progress on avelumab?

For patients with avelumab-refractory MCC, alternative immune checkpoint inhibitor combinations such as ipilimumab plus nivolumab have shown benefit in studies (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.